特布他林联合布地奈德雾化对支气管哮喘急性发作患者炎性因子的干预作用

Intervention Effect of Terbutaline Combined with Budesonide on Inflammatory Factors in Patients with Acute Exacerbation of Bronchial Asthma

目的探讨特布他林联合布地奈德对支气管哮喘急性发作患者炎性因子的干预作用。方法选取2016年2月至11月医院收治的支气管哮喘急性发作患者80例,按随机数字表法分为观察组和对照组,各40例。观察组采用特布他林联合布地奈德雾化治疗,对照组单用布地奈德雾化治疗。两组均治疗1~2周。结果观察组总有效率为97.50%,明显高于对照组的82.50%(P<0.05);治疗后,两组患者的白细胞介素(IL)-6,IL-17和肿瘤坏死因子(TNF)-α水平均显著下降,且观察组下降水平显著优于对照组(P<0.05),IL-10水平、第1秒用力呼气容积(FEV_1)和呼气峰流速(PEF)均显著升高,且观察组升高水平显著优于对照组(P<0.05);两组患者均未见严重不良反应发生。结论特布他林联合布地奈德治疗支气管哮喘急性发作,能显著改善患者的临床症状及体征,改善肺功能,降低炎性因子的过度表达,安全有效,值得临床推广。

Objective To investigate the intervention effect of terbutaline combined with budesonide on inflammatory factors in patients with acute exacerbation of bronchial asthma. Methods Eighty patients with acute exacerbation of bronchial asthma admitted to our hospital from February to November 2016 were divided into the observation group and the control group according to the random number table method,40 cases in each group. The observation group was treated with terbutaline and budesonide,aerosol inhalation,while the control group was treated with budesonide,aerosol inhalation. The two groups were treated for 1-2 weeks. Results The total effective rate in the observation group was 97. 50%,which was significantly higher than 82. 50% in the control group（ P〈0. 05）. After treatment,the levels of IL-6,IL-17 and TNF-α in the two groups was significantly lower than before treatment,and the observation group was significantly lower than the control group（ P〈0. 05）. The levels of IL-10,FEV_1 and PEF in the two groups were significantly increased（ P〈0. 05）,and the observation group was significantly higher than the control group（ P〈0. 05）. No serious adverse events occurred in both groups. Conclusion Terbutaline combined with budesonide on inflammatory factors in patients with acute exacerbation of bronchial asthma can significantly improve the clinical symptoms,improve lung function and reduce the over expression of inflammatory factors. It is safety,effective and worthy of clinical promotion.